Global Phenomenon Hits Korean Shores: The Sold-Out Sensation That’s Sweeping the World

Elon Musk’s Certification of Use: Wegobi Expected to Launch in Korea in October

Recently, a user of X (formerly Twitter) asked Elon Musk about his diet secrets after seeing his recent photos. Musk’s answer was simple: “Fasting. And Wegovy.” Wegovy, mentioned by Elon Musk, is a diet supplement that has recently been gaining attention as a global game changer in the pharmaceutical industry.

Wegobi: An Emerging Game Changer in the Pharmaceutical Industry

Wegobi (ingredient name: semaglutide) is a diet supplement developed by Novo Nordisk in 2012 and received approval from the US FDA in 2021. Semaglutide, an ingredient in Wegobi, has recently been receiving attention as research results have been published showing that it has an effect on various diseases such as arthritis, Alzheimer’s, cancer, and COVID-19.

In particular, research results are being reported one after another that it is not only effective for obesity and overweight, but also reduces the risk of death in patients with heart disease and slows down human aging. Although Wegobi received domestic product approval in April 2023, its domestic launch has been delayed due to increased international demand.

Ozempic: A Diabetes Treatment with a Surprising Effect on Infertility

Novo Nordisk, the manufacturer of Wegobi, also sells Ozempic, a diabetes treatment with the same ingredients, in addition to Wegobi. Ozempic is effective in controlling blood sugar and losing weight, and differs from Wegobi in terms of the semaglutide component and dosage.

Recently, through BBC broadcasts, many cases have been discovered where Ozempic has proven effective for infertile women, and children born as a result of the Ozempic effect have been named ‘Ozempic babies.’ However, there are many analyses that say that infertility is an additional phenomenon caused by the weight loss effect of Ozempic.

Novo Nordisk Leads Denmark’s GDP

According to recent foreign media reports, Denmark’s GDP growth rate this year is 1.8%, which is said to be ahead of other Nordic countries such as Sweden (1.2%) and Norway (0.7%). Danske Bank, Denmark’s largest bank, attributed Denmark’s performance to the global success of the country’s famous pharmaceutical company, Novo Nordisk, and analyzed that Novo Nordisk’s growth was driving half of Denmark’s GDP growth.

Novo Nordisk has now surpassed luxury goods powerhouse Moët Hennessy Louis Vuitton (LVMH) in market capitalization, establishing itself as a major European company. Novo Nordisk’s ‘Wigovi’ has not yet been launched in even 10 countries around the world. Novo Nordisk has faced supply shortages from last year to this year, but since market demand has been exceeding the entire time, attention is being paid to the future course of biotech stocks as investors’ sentiment has returned.